Astrazeneca

18 articles about Astrazeneca

• Ironwood Pharmaceuticals and AstraZeneca Amend LINZESS® (linaclotide) Collaboration in China

  9/18/2019

  Ironwood Pharmaceuticals, Inc. announced that it has amended its collaboration agreement with AstraZeneca for the development and commercialization of LINZESS in China.

• Mylan Expands Oncology Portfolio with Launch of Generic Faslodex® Injection, a Treatment for Advanced Breast Cancer

  9/17/2019

  Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product, which is used to treat certain types of advanced breast cancer in women who have experienced menopause as monotherapy and in advanced or metastatic breast cancer in combination with other products.

• FDA Grants Fast Track Designation for FARXIGA in Heart Failure

  9/16/2019

  AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of FARXIGA (dapagliflozin) to reduce the risk of cardiovascular (CV) death or the worsening of heart failure in adults with heart failure with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF).

• Imfinzi® (durvalumab) is the First Immunotherapy to Show Both Significant Survival Benefit and Improved, Durable Responses in Extensive-Stage Small Cell Lung Cancer

  9/12/2019

  Data presented at the IASLC 2019 World Conference on Lung Cancer demonstrated the Phase III CASPIAN trial of Imfinzi improved survival with either a cisplatin or carboplatin chemotherapy backbone

• IMFINZI Is First Immunotherapy to Show Both Significant Survival Benefit and Improved, Durable Responses in Extensive-Stage Small Cell Lung Cancer

  9/9/2019

  In the Phase III CASPIAN trial IMFINZI at a fixed, convenient dose improved survival with either a cisplatin or carboplatin chemotherapy backbone

• HCmed Innovations joins Wuxi International Life Science Innovation Park supported by AstraZeneca China

  9/7/2019

  Supported by the idea of garnering global wisdom to improve the healthcare system in China, Wuxi Municipal Government, Wuxi High-tech District, and AstraZeneca, as a founding partner, officially inaugurated Wuxi International Life Science Innovation Park on September 7, 2019.

• Theragnostics Signs Agreement With Astrazeneca

  9/5/2019

  Theragnostics announces a licence agreement with AstraZeneca for intellectual property (IP) that enables Theragnostics’ freedom to operate globally in the diagnostic field of certain selected radionuclide-labelled PARPi Polymerase inhibitors) with an option to an exclusive licence for freedom to operate globally in the therapeutic field of certain selected radionuclide-labelled PARPi.

• Schrödinger Announces Collaboration with AstraZeneca to Deploy Advanced Computing Technology for Drug Discovery

  9/4/2019

  Schrödinger announced a collaboration with AstraZeneca to deploy Schrödinger’s advanced computing platform to help accelerate drug discovery efforts.

• Detailed Results from Phase III DAPA-HF Trial Showed FARXIGA Significantly Reduced Both the Incidence of Cardiovascular Death and the Worsening of Heart Failure

  9/1/2019

  DAPA-HF is the first outcomes trial with an SGLT2 inhibitor in patients with heart failure with reduced ejection fraction, with and without type 2 diabetes

• BRILINTA Reduced the Risk of Cardiovascular Events in Patients With Coronary Artery Disease and Type 2 Diabetes in Phase III THEMIS Trial

  9/1/2019

  AstraZeneca announced detailed results from the positive Phase III THEMIS trial, which showed BRILINTA plus aspirin reduced the relative risk for the composite of cardiovascular death, heart attack, or stroke by 10% compared with aspirin alone, a statistically significant reduction.

• PT010 Phase III ETHOS Trial Met Its Primary Endpoint in COPD

  8/29/2019

  AstraZeneca announced positive results from the Phase III ETHOS trial for triple-combination therapy PT010 in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

• PT010 Phase III ETHOS trial met its primary endpoint in chronic obstructive pulmonary disease

  8/28/2019

  AstraZeneca announced positive results from the Phase III ETHOS trial for triple-combination therapy PT010 in patients with moderate to very severe chronic obstructive pulmonary disease.

• FARXIGA Met Primary Endpoint in Landmark Phase III DAPA-HF Trial for the Treatment of Patients With Heart Failure

  8/20/2019

  DAPA-HF is the first heart failure outcomes trial with an SGLT2 inhibitor in patients with and without type 2 diabetes

• LYNPARZA® (olaparib) Phase III Paola-1 Trial Met Primary Endpoint as 1st-line Maintenance Treatment With Bevacizumab for Advanced Ovarian Cancer

  8/14/2019

  AstraZeneca and Merck’s LYNPARZA when added to standard-of-care bevacizumab significantly increased the time women lived without disease progression or death

• TAGRISSO® (OSIMERTINIB) Significantly Improves Overall Survival in the Phase III FLAURA Trial for 1st-line EGFR-mutated Non-small Cell Lung Cancer

  8/9/2019

  TAGRISSO is the only medicine demonstrating statistically-significant overall survival benefit in this setting. Also increased the time patients with central nervous system metastases lived without disease progression

• LYNPARZA® (Olaparib) Phase III Profound Trial in HRR* Mutation-Selected Metastatic Castration-Resistant Prostate Cancer Met Primary Endpoint

  8/7/2019

  AstraZeneca and Merck, known as MSD outside the United States and Canada, announced positive results from the Phase III PROfound trial of LYNPARZA 300 mg twice daily in men with metastatic castration-resistant prostate cancer who have a *homologous recombination repair gene mutation and have failed prior treatment with new hormonal anticancer agents.

• LYNPARZA® (olaparib) Phase 3 PROfound Trial in HRR Mutation-Selected Metastatic Castration-Resistant Prostate Cancer Met Primary Endpoint

  8/7/2019

  AstraZeneca and Merck, known as MSD outside the United States and Canada, announced positive results from the Phase 3 PROfound trial of LYNPARZA in men with metastatic castration-resistant prostate cancer who have an homologous recombination repair gene mutation and have progressed on prior treatment with new hormonal anticancer treatments.

• BIOCARDIA SIGNS EXCLUSIVE DEVELOPMENT AGREEMENT WITH ASTRAZENECA

  7/29/2019

  BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced it has signed an extension to a 2017 development agreement with AstraZeneca [NYSE:AZN] for BioCardia’s Helix™ biotherapeutic delivery catheter system.